- Main
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.
- Habtehyimer, Feben;
- Zhu, Xianming;
- Redd, Andrew;
- Gebo, Kelly;
- Abraham, Alison;
- Patel, Eshan;
- Laeyendecker, Oliver;
- Gniadek, Thomas;
- Fernandez, Reinaldo;
- Baker, Owen;
- Ram, Malathi;
- Currier, Judith;
- Fukuta, Yuriko;
- Gerber, Jonathan;
- Heath, Sonya;
- Meisenberg, Barry;
- Huaman, Moises;
- Levine, Adam;
- Shenoy, Aarthi;
- Anjan, Shweta;
- Blair, Janis;
- Cruser, Daniel;
- Hammitt, Laura;
- Kassaye, Seble;
- Mosnaim, Giselle;
- Patel, Bela;
- Paxton, James;
- Raval, Jay;
- Sutcliffe, Catherine;
- Abinante, Matthew;
- Oei, Kevin;
- Cluzet, Valerie;
- Cordisco, Marie;
- Greenblatt, Benjamin;
- Rausch, William;
- Shade, David;
- Gawad, Amy;
- Klein, Sabra;
- Pekosz, Andrew;
- Shoham, Shmuel;
- Casadevall, Arturo;
- Bloch, Evan;
- Hanley, Daniel;
- Tobian, Aaron;
- Sullivan, David;
- Forthal, Donald;
- Cachay, Edward
- et al.
Published Web Location
https://doi.org/10.1128/spectrum.03286-23Abstract
This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-